US 11,951,213 B2
Synthetic progestogens and pharmaceutical compositions comprising the same
Philippe Perrin, Paris (FR); Jose Luis Velada, Amersfoort (NL); and Dominique Drouin, Verrieres-le-Buisson (FR)
Assigned to LABORATORIOS LEON FARMA SA, Leon (ES)
Filed by LABORATORIOS LEON FARMA SA, Leon (ES)
Filed on Aug. 4, 2023, as Appl. No. 18/365,877.
Application 18/365,877 is a continuation of application No. 17/967,767, filed on Oct. 17, 2022.
Application 17/967,767 is a continuation of application No. 17/856,605, filed on Jul. 1, 2022, granted, now 11,504,334, issued on Nov. 22, 2022.
Application 17/856,605 is a continuation of application No. 17/693,243, filed on Mar. 11, 2022, granted, now 11,413,249, issued on Aug. 16, 2022.
Application 17/693,243 is a continuation of application No. 17/684,261, filed on Mar. 1, 2022, granted, now 11,351,122, issued on Jun. 7, 2022.
Application 17/684,261 is a continuation of application No. 17/508,785, filed on Oct. 22, 2021, granted, now 11,291,633, issued on Apr. 5, 2022.
Application 17/508,785 is a continuation of application No. 17/346,139, filed on Jun. 11, 2021, granted, now 11,291,632, issued on Apr. 5, 2022.
Application 17/346,139 is a continuation of application No. 17/216,419, filed on Mar. 29, 2021, granted, now 11,123,299, issued on Sep. 21, 2021.
Application 17/216,419 is a continuation of application No. 17/105,300, filed on Nov. 25, 2020, granted, now 10,987,364, issued on Apr. 27, 2021.
Application 17/105,300 is a continuation of application No. 16/663,949, filed on Oct. 25, 2019, abandoned.
Application 16/663,949 is a continuation of application No. 13/171,410, filed on Jun. 28, 2011, granted, now 10,849,857, issued on Dec. 1, 2020.
Claims priority of provisional application 61/368,396, filed on Jul. 28, 2010.
Prior Publication US 2023/0372248 A1, Nov. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/585 (2006.01); A61K 9/16 (2006.01); A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61K 9/48 (2006.01); A61K 31/567 (2006.01); A61K 45/06 (2006.01); A61K 47/10 (2017.01); A61K 47/32 (2006.01); A61K 47/36 (2006.01); A61K 47/38 (2006.01)
CPC A61K 9/2054 (2013.01) [A61K 9/1605 (2013.01); A61K 9/1688 (2013.01); A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/2806 (2013.01); A61K 9/4841 (2013.01); A61K 31/567 (2013.01); A61K 31/585 (2013.01); A61K 45/06 (2013.01); A61K 47/10 (2013.01); A61K 47/32 (2013.01); A61K 47/36 (2013.01); A61K 47/38 (2013.01); A61K 9/2866 (2013.01); A61K 9/4816 (2013.01)] 14 Claims
 
1. A method for providing effective contraception in a female patient over a 28-day period, comprising administering 24 scheduled daily oral doses of a pharmaceutical composition comprising from 2 mg to 6 mg of 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone to the female patient within a 24-day period, followed by a 4-day period wherein the daily oral dose is not administered, wherein the pharmaceutical composition does not comprise estrogen, and wherein administration of up to two non-consecutive scheduled daily oral doses may be delayed up to 24 hours from the scheduled daily administration, and the effective contraception is maintained when the up to two non-consecutive scheduled daily oral doses are delayed.